Importance of Tissue Perfusion in ST Segment Elevation Myocardial Infarction Patients Undergoing Reperfusion Strategies: Role of Adenosine
Open Access
- 14 November 2007
- journal article
- Published by Wiley in Clinical Cardiology
- Vol. 30 (11) , 583-585
Abstract
High risk ST segment elevation myocardial infarction (STEMI) patients undergoing reperfusion therapy continue to exhibit significant morbidity and mortality due in part to myocardial reperfusion injury. Importantly, preclinical studies demonstrate that progressive microcirculatory failure (the “no‐reflow” phenomenon) contributes significantly to myocardial reperfusion injury. Diagnostic techniques to measure tissue perfusion have validated this concept in humans, and it is now clear that abnormal tissue perfusion occurs frequently in STEMI patients undergoing reperfusion therapy. Moreover, because tissue perfusion correlates poorly with epicardial blood flow (TIMI flow grade), clinical studies show that tissue perfusion is an independent predictor of early and late mortality in STEMI patients and is associated with infarct size, ventricular function, CHF and ventricular arrhythmias. The mechanisms responsible for abnormal tissue perfusion are multifactorial and include both mechanical obstruction and vasoconstrictor humoral factors. Adenosine, an endogenous nucleoside, maintains microcirculatory flow following reperfusion by activating four well‐characterized extracellular receptors. Because activation of adenosine receptors attenuates the mechanical and functional mechanisms leading to the “no reflow” phenomenon and activates other cardioprotective pathways as well, it is not surprising that both experimental and clinical studies show striking myocardial salvage with intravenous infusions of adenosine administered in the peri‐reperfusion period. For example, a post hoc analysis of the AMISTAD II trial indicates a significant reduction in 1 and 6‐month mortality in STEMI patients undergoing reperfusion therapy who are treated with adenosine within 3 hours of symptoms. In conclusion, adenosine's numerous cardioprotective effects, including attenuation of the “no‐reflow” phenomenon, support its use in high risk STEMI undergoing reperfusion. CopyrightKeywords
This publication has 9 references indexed in Scilit:
- Effect of No-Reflow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction on Six-Month MortalityThe American Journal of Cardiology, 2007
- Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trialEuropean Heart Journal, 2006
- Role of Adenosine as Adjunctive Therapy in Acute Myocardial InfarctionCardiovascular Drug Reviews, 2006
- Myocardial endothelin-1 release and indices of inflammation during angioplasty for acute myocardial infarction and stable coronary artery diseaseAmerican Heart Journal, 2004
- Angiographic perfusion score: An angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarctionAmerican Heart Journal, 2004
- Coronary and Myocardial AngiographyCirculation, 2004
- Elevations in Troponin T and I Are Associated With Abnormal Tissue Level PerfusionCirculation, 2002
- Intracoronary serotonin release after high-pressure coronary stentingThe American Journal of Cardiology, 1999
- Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator.Circulation, 1989